Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | CD22 | P20273 | 7/20 | 0.40 |
| ▸ | MAG | P20916 | 5/20 | 0.40 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066109 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL28161285 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL13839153 | 0.88 | NANP (0.49) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL2742889 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL8489507 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL15976325 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL13125452 | 0.88 | NANP (0.74) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL15321632 | 0.87 | NANP (0.61) | NANPCD22MAG | |
| SCHEMBL17722651 | 0.87 | NANP (0.63) | NANPL3MBTL1SELLSELPCD22 | |
| SCHEMBL17000127 | 0.87 | NANP (0.63) | NANPL3MBTL1SELLSELPCD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120953-A1 | Factor VIII Conjugates | NOVO NORDISK AS (DK) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120953-A1 | Factor VIII Conjugates | F8, F13B, F13A1 | NANP 627/4885L3MBTL1 3953/4885SELL 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.